Sold as Xolremdi. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Mavorixafor (sold as Xolremdi), first approved Apr 26, 2024, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Xolremdi | Part D | $636K | New | 0 |
| A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersAcquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia · X4 Pharmaceuticals | Phase 2 | Not yet recruiting | Oct 29, 2026 |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsNeutropenia · X4 Pharmaceuticals | Phase 3 | Recruiting | Sep 28, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
